SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. You have free access to this content1
    Handoo Rhee, Jennifer H. Gunter, Peter Heathcote, Ken Ho, Phillip Stricker, Niall M. Corcoran, Colleen C. Nelson, Adverse effects of androgen-deprivation therapy in prostate cancer and their management, BJU International, 2015, 115,
  2. 2
    A. N. Damji, K. Bies, S. M. H. Alibhai, J. M. Jones, Bone health management in men undergoing ADT: examining enablers and barriers to care, Osteoporosis International, 2015, 26, 3, 951

    CrossRef

  3. 3
    Noel W. Clarke, Balancing Toxicity and Efficacy: Learning from Trials and Treatment Using Antiresorptive Therapy in Prostate Cancer, European Urology, 2014, 65, 2, 287

    CrossRef

  4. You have free access to this content4
    Carol E. DeSantis, Chun Chieh Lin, Angela B. Mariotto, Rebecca L. Siegel, Kevin D. Stein, Joan L. Kramer, Rick Alteri, Anthony S. Robbins, Ahmedin Jemal, Cancer treatment and survivorship statistics, 2014, CA: A Cancer Journal for Clinicians, 2014, 64, 4
  5. 5
    Whoon J. Kil, Nancy P. Mendenhall, Christopher G. Morris, R. Charles Nichols, Randal H. Henderson, William M. Mendenhall, Curtis Bryant, Christopher Williams, Zuofeng Li, Bradford S. Hoppe, Patient-reported Hip Symptoms following Treatment with Proton Therapy for Prostate Cancer, International Journal of Particle Therapy, 2014, 1, 1, 14

    CrossRef

  6. 6
    Francesco Ricci, Giulia Buzzatti, Alessandra Rubagotti, Francesco Boccardo, Safety of antiandrogen therapy for treating prostate cancer, Expert Opinion on Drug Safety, 2014, 13, 11, 1483

    CrossRef

  7. 7
    Landon W. Trost, Ege Serefoglu, Ahmet Gokce, Brian J. Linder, Alton O. Sartor, Wayne J.G. Hellstrom, Androgen Deprivation Therapy Impact on Quality of Life and Cardiovascular Health, Monitoring Therapeutic Replacement, The Journal of Sexual Medicine, 2013, 10,
  8. 8
    S. M. H. Alibhai, H. Z. Mohamedali, H. Gulamhusein, A. H. Panju, H. Breunis, N. Timilshina, N. Fleshner, M. D. Krahn, G. Naglie, I. F. Tannock, G. Tomlinson, P. Warde, S. Duff Canning, A. M. Cheung, Changes in bone mineral density in men starting androgen deprivation therapy and the protective role of vitamin D, Osteoporosis International, 2013, 24, 10, 2571

    CrossRef

  9. You have free access to this content9
    Yu-Hsuan Shao, Dirk F. Moore, Weichung Shih, Yong Lin, Thomas L. Jang, Grace L. Lu-Yao, Fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications, BJU International, 2013, 111, 5
  10. 10
    Raul Valery, Nancy P. Mendenhall, Romaine C. Nichols, Randal Henderson, Christopher G. Morris, Zhong Su, William M. Mendenhall, Christopher R. Williams, Zuofeng Li, Bradford S. Hoppe, Hip fractures and pain following proton therapy for management of prostate cancer, Acta Oncologica, 2013, 52, 3, 486

    CrossRef

  11. 11
    Robert E. Coleman, Emma Rathbone, Janet E. Brown, Management of cancer treatment-induced bone loss, Nature Reviews Rheumatology, 2013, 9, 6, 365

    CrossRef

  12. 12
    K. N. Kelly, C. Kelly, Pattern and cause of fractures in patients who abuse alcohol: what should we do about it?, Postgraduate Medical Journal, 2013, 89, 1056, 578

    CrossRef

  13. 13
    Mona Al Mukaddam, Peter J. Snyder, Osteoporosis, 2013,

    CrossRef

  14. 14
    Lawrence Drudge-Coates, Bruce Turner, Bone micro-environment in prostate cancer: impact, treatment and implications for nursing practice, International Journal of Urological Nursing, 2012, 6, 2
  15. 15
    Andreas Thorstenson, Ola Bratt, Olof Akre, Henrik Hellborg, Lars Holmberg, Mats Lambe, Anna Bill-Axelson, Pär Stattin, Jan Adolfsson, Incidence of fractures causing hospitalisation in prostate cancer patients: Results from the population-based PCBaSe Sweden, European Journal of Cancer, 2012, 48, 11, 1672

    CrossRef

  16. 16
    M.N.G. Dukes, A worldwide yearly survey of new data in adverse drug reactions and interactions, 2012,

    CrossRef

  17. 17
    Vivek K. Wadhwa, Robin Weston, Nigel J. Parr, Bicalutamide monotherapy preserves bone mineral density, muscle strength and has significant health-related quality of life benefits for osteoporotic men with prostate cancer, BJU International, 2011, 107, 12
  18. 18
    Rebecca Silbermann, G. David Roodman, Bone effects of cancer therapies, Current Opinion in Supportive and Palliative Care, 2011, 5, 3, 251

    CrossRef

  19. 19
    Valerie D'Alesio, Brent E. Salvig, T. Neal Fourakre, Evaluation of Osteoporosis Risk Assessment in Veterans Receiving Androgen-Deprivation Therapy, The Consultant Pharmacist, 2011, 26, 1, 43

    CrossRef

  20. 20
    R. Mistry, D. Hughes, V. Wadhwa, N. Parr, Lateral Spine Radiographs Before Androgen Deprivation Treatment Detect a High Incidence of Undiagnosed Vertebral Fragility Fractures in Men With Advanced Prostate Cancer, The Journal of Urology, 2011, 186, 2, 474

    CrossRef

  21. 21
    Vivek K. Wadhwa, Robin Weston, Nigel J. Parr, Frequency of zoledronic acid to prevent further bone loss in osteoporotic patients undergoing androgen deprivation therapy for prostate cancer, BJU International, 2010, 105, 8
  22. 22
    Frank Kunath, Henrik R Grobe, Gerta Rücker, Edith Motschall, Gerd Antes, Philipp Dahm, Bernd Wullich, Joerg J Meerpohl, Non-steroidal antiandrogen monotherapy compared with luteinising hormone–releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer, The Cochrane Library,